explore -WSS

explore

author：knowledge 2025-09-28 21:57:33 - browse：8

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： How faith leaders like me can help address America's obesity epidemic

Wikipedia

WSS

California wildfire smoke linked to 52,000 early deaths, study says

Problems with a popular proposal to regulate AI in health care

ALS patient reclaims some autonomy thanks to wearable 'robot'

California wildfire smoke linked to 52,000 early deaths, study says

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Statins may not be needed by millions of people, study suggests

knowledge

explore

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NIH tests clinical research in primary care with $30 million program

Sports medicine is finally prioritizing gender equality

Medical device trials still don't enroll enough women, study finds

Cancer drug shortages should be causing more outrage

Medical device trials still don't enroll enough women, study finds

How one medical school became remarkably diverse

STAT Virtual Event: ASCO Recap, Live!

Medical records are filled with copy

The Biogen Aduhelm mess could happen again

Wikipedia

STAT Virtual Event: ASCO Recap, Live!

Texas Medical Board asked to define abortion emergency exception

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Deposition: Sackler embraced plan to conceal OxyContin’s strength

My daughter's legacy lives on through her writing, phage therapy

Wikipedia

knowledge

focus

focus